Ongoing clinical studies of ifosfamide for pediatric cancer in the United States.
This article gives highlights of ongoing pediatric solid tumor and leukemia trials in the United States that use ifosfamide in combination with mesna. These trials are being carried out both by large cooperative groups and single institutions. Some role for ifosfamide with mesna in the front-line treatment of sarcomas is assured. Neurotoxicity, nephrotoxicity, and other unusual toxicities are discussed.
Pratt
C B
CB
Department of Hematology-Oncology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002986:Clinical Trials as Topic; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007938:Leukemia / Q000188:drug therapy; D015080:Mesna / Q000008:administration & dosage / Q000009:adverse effects; D015337:Multicenter Studies as Topic; D009369:Neoplasms / Q000188:drug therapy*; D012509:Sarcoma / Q000188:drug therapy; D014481:United States
D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D015080:Mesna; D007069:Ifosfamide